Core Viewpoint - The company Baillie Gifford has announced the completion of the first patient enrollment in a Phase III clinical trial for its innovative biopharmaceutical T-Bren (HER2ADC), which is being compared to pembrolizumab combined with platinum-based chemotherapy for first-line treatment of advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations [1] Group 1 - T-Bren (BL-M07D1) is a targeted HER2 innovative ADC with best-in-class potential, demonstrating significant anti-tumor efficacy in clinical trials [1] - The Phase III clinical study comparing T-Bren to pembrolizumab combined with platinum-based chemotherapy has recently entered its third phase and completed the first patient enrollment [1] Group 2 - Currently, T-Bren is involved in 14 clinical trials domestically and internationally, including 5 Phase III, 1 Phase II/III, 2 Phase II, 3 Phase I/II, and 3 Phase I trials [1] - The trials cover various indications, including first-line and second-line HER2-positive breast cancer, post-operative adjuvant therapy for HER2-positive breast cancer, neoadjuvant therapy for HER2-positive breast cancer, HER2 low-expressing breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, and HER2-mutated non-squamous non-small cell lung cancer, as well as other cancers such as lung, gastrointestinal, urological, and gynecological tumors [1]